These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21136375)

  • 21. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma.
    Walker CL; Burroughs KD; Davis B; Sowell K; Everitt JI; Fuchs-Young R
    J Soc Gynecol Investig; 2000; 7(4):249-56. PubMed ID: 10964025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Synchronous development of carcinosarcoma of the uterine body and secondary cancer of the ovary].
    Budiak VA; Vasilevitskaia AG; Soloveĭ PF; Poluéktov IuA; Khodosevich NV; Teteriadchenko TE
    Klin Khir (1962); 1992; (5):64-6. PubMed ID: 1507775
    [No Abstract]   [Full Text] [Related]  

  • 23. [Carcinosarcoma of the corpus uteri--a case report].
    Amălinei C; Căruntu ID; Balan R; Cotuţiu C; Bădescu M
    Rev Med Chir Soc Med Nat Iasi; 1997; 101(1-2):213-7. PubMed ID: 10756758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
    Ganz PA; Land SR
    Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of tamoxifen response: what have we learned?
    Lash TL; Ahern TP; Cronin-Fenton D; Garne JP; Hamilton-Dutoit S; Kvistgaard ME; Rosenberg CL; Silliman RA; Sørensen HT
    J Clin Oncol; 2008 Apr; 26(10):1764-5; author reply 1765-6. PubMed ID: 18375910
    [No Abstract]   [Full Text] [Related]  

  • 26. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant tamoxifen.
    Booth CM; Pater JL; Goss PE
    Cancer; 2007 May; 109(9):1927-8; author reply 1928. PubMed ID: 17354227
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effects of raloxifene on other organs without bone: uterus].
    Nozaki M
    Clin Calcium; 2004 Oct; 14(10):55-60. PubMed ID: 15577132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of breast cancer using selective oestrogen receptor modulators (SERMs).
    Powles TJ
    Breast Cancer Res; 2006; 8(5):111. PubMed ID: 17049068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoprevention of breast cancer: recommendations and rationale.
    Berg AO;
    Am J Nurs; 2003 May; 103(5):107, 109, 111, 113. PubMed ID: 12759615
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical analysis of 12 cases of uterine carcinosarcoma].
    Wang LH; Xiong Y; Li YF; Li JD; Feng YL; Li YJ; Chen C; Chen L
    Ai Zheng; 2008 May; 27(5):516-9. PubMed ID: 18479602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer.
    de Souza Sales JF; Cabello C; Alvarenga M; Torresan RZ; Duarte GM
    Breast; 2007 Apr; 16(2):197-203. PubMed ID: 17178225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does ER-betacx really have no clinical importance in tamoxifen-treated breast cancer patients?
    Palmieri C; Gojis O; Rudraraju B; Cleator S
    J Clin Oncol; 2008 Dec; 26(35):5824; author reply 5825-6. PubMed ID: 19001345
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene.
    Lee WL; Cheng MH; Chao HT; Wang PH
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):24-31. PubMed ID: 18400579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitors: a time for reflection.
    Birge SJ
    Menopause; 2007; 14(6):971-2. PubMed ID: 17975522
    [No Abstract]   [Full Text] [Related]  

  • 35. [SERM--selective estrogen receptor modulators].
    Kønig KB; Eiken PA; Schwarz P
    Ugeskr Laeger; 2001 Apr; 163(15):2129-33. PubMed ID: 11332210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selective estrogen-receptor modulators for primary prevention of breast cancer.
    Fabian CJ; Kimler BF
    J Clin Oncol; 2005 Mar; 23(8):1644-55. PubMed ID: 15755972
    [No Abstract]   [Full Text] [Related]  

  • 37. [Additional effect of SERM: mammary gland].
    Kurebayashi J
    Clin Calcium; 2004 Oct; 14(10):47-51. PubMed ID: 15577131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.
    Riggs BL; Hartmann LC
    N Engl J Med; 2003 Feb; 348(7):618-29. PubMed ID: 12584371
    [No Abstract]   [Full Text] [Related]  

  • 39. Bone builder vs. breast cancer.
    Johns Hopkins Med Lett Health After 50; 2007 Jan; 18(11):1-2. PubMed ID: 17323491
    [No Abstract]   [Full Text] [Related]  

  • 40. [Contribution to carcinosarcoma of the uterus (author's transl)].
    Brandt M; Marzotko F
    Zentralbl Allg Pathol; 1977; 121(1-2):129-33. PubMed ID: 848168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.